{
    "2018-11-05": [
        [
            {
                "time": "",
                "original_text": "【中银医药】医药生物行业2018年三季报综述——行业整体收入和扣非利润保持20%的增速中枢",
                "features": {
                    "keywords": [
                        "医药生物",
                        "三季报",
                        "收入",
                        "扣非利润",
                        "20%增速"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：创新升级大势所趋 荐9股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "创新升级",
                        "荐股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}